A Blueprint for Assessing Affordability of SGLT2 Inhibitors in the United States: The Cost-Effectiveness of Dapagliflozin in Three European Countries

Clin J Am Soc Nephrol. 2022 Dec;17(12):1707-1709. doi: 10.2215/CJN.09900822. Epub 2022 Nov 2.

Annika Khine¹, Eugene Lin^{2

3

4}

¹ Department of Medicine, Los Angeles County + University of Southern California Medical Center, Los Angeles, California.
² Department of Medicine, Division of Nephrology, Keck School of Medicine of the University of Southern California, Los Angeles, California eugene.lin@med.usc.edu.
³ The Leonard D. Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles, California.
⁴ Department of Health Policy & Management, Sol Price School of Public Policy, University of Southern California, Los Angeles, California.

No abstract available

Keywords: chronic kidney disease; economic analysis; progression of chronic renal failure.

Publication types